Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use POMBILITI® safely and effectively. See full prescribing information for POMBILITI. POMBILITI (cipaglucosidase alfa-atga) for injection, for intravenous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).
- generic_name
- cipaglucosidase alfa-atga
- product_names
- cipaglucosidase alfa-atga
- ndc
- 71904-200, 71904-200-01, 71904-200-02, 71904-200-03
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en